U.S. Department of Health & Human Services
National Institutes of Health
NCATS
This repository is under review for potential modification in compliance with Administration directives.
Dismiss
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
RELATLIMAB
AF75XOF6W3
US Approved Rx (2022)
First approved in 2022
General
Names
8
Classification
3
Identifiers
11
Subunits
4
Related Substances
1
RELATLIMAB
AF75XOF6W3
US Approved Rx (2022)
First approved in 2022
General
Approval Year
2022
324
Names
8
Show
5
20
100
All
entries
Name
Type
Language
Name
Type
Language
BMS-986016
Preferred Name
English
RELATLIMAB
Official Name
English
IMMUNOGLOBULIN G4, ANTI-(HUMAN LYMPHOCYTE ACTIVATION GENE-3 PROTEIN) (HUMAN HEAVY CHAIN), DISULFIDE WITH HUMAN LIGHT CHAIN, DIMER
Systematic Name
English
BMS-986213 COMPONENT RELATLIMAB
Common Name
English
relatlimab [INN]
Common Name
English
Showing 1 to 5 of 8 entries
Previous
1
2
Next
Classification
3
Show
5
20
100
All
entries
Classification Tree
Code System
Code
Classification Tree
Code System
Code
Designated
ORPHAN DRUG
Designated
Treatment of gastric cancer (GC) and gastro-esophageal junction cancer (GEJ).
FDA ORPHAN DRUG
641718
Designated/Approved
ORPHAN DRUG
Designated/Approved
Treatment of stage IIb to IV melanoma
FDA ORPHAN DRUG
595017
Monoclonal Antibody
Pharmacologic Substance
[C1909]
Biological Agent
[C307]
Monoclonal Antibody
[C20401]
Anti-LAG-3 Monoclonal Antibody
NCI_THESAURUS
C134305
Showing 1 to 3 of 3 entries
Previous
1
Next
Identifiers
11
Show
5
20
100
All
entries
Code System
Code
Type
Description
Code System
Code
Type
Description
DRUG BANK
DB14851
PRIMARY
NCI_THESAURUS
C111999
PRIMARY
CAS
1673516-98-7
PRIMARY
INN
10735
PRIMARY
RXCUI
2596773
PRIMARY
Showing 1 to 5 of 11 entries
Previous
1
2
3
Next
Subunits
4
Subunit 0
>SUBUNIT_0
Subunit 1
>SUBUNIT_1
Subunit 2
>SUBUNIT_2
Subunit 3
>SUBUNIT_3
Related Substances
1
ACTIVE MOIETY
AF75XOF6W3
RELATLIMAB
